Skip to main content
. Author manuscript; available in PMC: 2016 Feb 9.
Published in final edited form as: Breast Cancer Res Treat. 2009 Sep 26;122(2):307–314. doi: 10.1007/s10549-009-0556-1

Figure 4.

Figure 4

NMDAR1 receptors appear to be important for in vitro proliferation of breast cancer cells. Depiction of data as percentage reduction in cell viability (means ± SEM) produced by different concentrations of irreversible NMDAR1 receptor antagonist MK-801(dizocilpine maleate) on (A) MCF-7 cells, and (B) SKBR3 cells, after 24 h (□), 48 h (●) and 72 h (△) of treatment. Cell viability was assessed using Alamar Blue and was reduced to about 10% of control. Reductions were highly significant (p<0.0001) and IC50s were obtained with ~500–600 μM doses of antagonist at 48 and 72 hours of incubation.